108 SERUM TRANSFORMING GROWTH FACTOR-BETA 1 AS A BIOMARKER OF INCIDENT AND PROGRESSIVE RADIOGRAPHIC OSTEOARTHRITIS AT THE KNEE: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT  by Nelson, A.E. et al.
Osteoarthritis and Cartilage Vol. 17, Supplement 1 S65
107
LOCAL MEASUREMENTS OF AGGRECAN AND CARTILAGE
OLIGOMERIC MATRIX PROTEIN WITH MICRODIALYSIS
TECHNIQUE IN PATIENTS WITH OSTEOARTHRITIS OF THE
KNEE
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C. Nordentoft, H. Christensen, H. Langberg, M. Kjær
Bispebjerg Hosp., Copenhagen, Denmark
Purpose: The treatment of osteoarthritis (OA) is limited by sparse
knowledge of the pathogenesis, which can be partly related to lack
of investigative methods to obtain continuous recordings in joint
and joint-near tissue. Microdialysis is a minimally invasive method
which allows for continuous determination of substances locally
and in vivo. In this study we have examined levels of 2 biomarkers
of cartilage, Cartilage Oligomeric Matrix Protein (COMP) and
Aggrecan, measured by microdialysis in 2 different regions of the
knee.
Methods: Subjects with conﬁrmed OA were regionally anaesthe-
sized and 2 microdialysis catheters containing a 3 cm region with
pores allowing for molecules of a size up to 3000 kDa to pass
the membrane, were positioned under ultrasonographic guidance.
One was placed intraarticularly in the suprapatellar pouch and
another one outside the joint but synovium-close in the medial
parapatellar region. The microdialysis catheters were perfused at
a slow rate with Ringer-acetate solution and radioactively labelled
glucose allowing for determination of relative recovery (RR) of
the catheters. Samples were collected continuously for a period
ranging from 100 - 180 min for each subject.
Results: Mean RR, an indicator of membrane functionality, was
56±12% for the intraarticular catheters and 52±15% for the
synovium-close catheters.
Aggrecan and COMP levels in the dialysate were measured by
ELISA and later corrected for RR. Synovium-close and intraartic-
ular levels of Aggrecan ranged from 21.70 to 92.95 ng/ml (n = 13)
and 53.25 to 731.80 ng/ml (n = 8) respectively (Fig. 1), and simi-
larly we found levels of COMP to range from 6.69 to 47.12 U/l (n =
8) intraarticularly and 2.70 to 18.14 U/l (n = 9) synovium-close (Fig.
2). Both Aggrecan and COMP concentrations were signiﬁcantly
higher intraarticularly than in the synovium-near extraarticular tis-
sue. Serum levels of both markers were also determined and were
in the range of previous studies on OA patients.
Figure 1. Levels of Aggrecan measured intraarticularly (I.A) and synovium-close
(Syn) by microdialysis. Values corrected for relative recovery (p<0.05 on log-
transformed data).
Conclusions: Microdialysis of the knee with OA has never been
done before. This study demonstrates that it is possible to perform
this and to obtain relative recoveries comparable to those of other
studies where microdialysis has been used in other types of
Figure 2. Levels of Cartilage Oligomeric Matrix Protein (COMP) measured in-
traarticularly (I.A.) and synovium-close (Syn) by microdialysis. Values corrected
for relative recovery (p<0.05 on log-transformed data).
tissue. Levels of Aggrecan and COMP have for the ﬁrst time been
measured continuously, both within the joint and peri-synovial, and
it was found that peri-synovial concentrations were not as high as
the intraarticular ones.
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Purpose: Our group recently published a cross-sectional study
of the utility of transforming growth factor-beta 1 (TGF-β1) as
a biomarker of OA, showing no signiﬁcant association between
serum TGF-β1 levels and the presence or severity of radiographic
OA (rOA) at the knee or hip [1]. The current longitudinal analysis
was designed to test the utility of serum TGF-β1, as a predictor
of incident and progressive rOA at the knee in African Americans
(AAs) and Caucasians.
Methods: Baseline serum TGF-β1 levels were available for 330
participants in the Johnston County Osteoarthritis Project. Serum
TGF-β1 was measured using a sandwich ELISA kit from Biosource
International (Camarillo, CA); manufacturer reported precision was
5.5-6.2% intra-assay and 6.6-7.9% inter-assay. Paired longitudinal
knee ﬁlms were available for 329 individuals (658 knees). Incident
knee rOA was deﬁned in two ways: 1) development of K-L grade
≥2 in a knee with K-L grade <2 at baseline, and 2) development of
K-L grade ≥1 in a knee with K-L grade=0 at baseline. Progression
of knee rOA was also deﬁned in two ways: 1) an increase by ≥1 K-
L grade in a knee that was a K-L grade ≥2 at baseline, and 2) an in-
crease by ≥1 K-L grade in a knee that was a K-L grade ≥1 at base-
line. Incident osteophytes and joint space narrowing (JSN) were
identiﬁed in knees with an OST or JSN grade of 0 at baseline and
≥1 at follow-up; progression in OST and JSN was deﬁned as an in-
crease of ≥ 1 grade in a knee with at least grade 1 at baseline. The
natural logarithm transformation was used to produce near-normal
distributions for serum TGF-β1 (ln TGF-β1), which was used as a
continuous variable in analyses. Multivariable time-to-event regres-
sion models using the Weibull distribution were used to provide
hazard ratios for each one-unit increase in the level of serum
lnTGF-β1 with rOA outcomes, accounting for variable follow up
times (interval censoring) and clustering of 2 knees per individual.
Interaction terms were considered signiﬁcant at the p <0.01 level.
Results: The mean (±SD) age of the sample was 62±10 years,
and the mean BMI was 30±7 kg/m2; 61% were women and 42%
were AA. The mean (± SD) serum TGF-β1 was 17.8±6.1 ng/ml
(range 6.1-40.9 ng/ml), and the mean (± SD) follow up time was
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Abstract 108 – Table 1. Adjusted* Hazard Ratios for TGF-β1 and OA Outcomes
Deﬁnition of OA Outcomes n Adjusted HR* p value
(knees with outcome) (95%CI)
Incident rOA (from baseline K-L<2 to K-L ≥ 2) 103 1.10 (0.46-2.63) 0.83
Incident rOA (from baseline K-L<1 to K-L ≥ 1) 94 1.04 (0.41-2.65) 0.93
Incident OST (from grade 0 to grade ≥ 1) 94 1.41 (0.56-3.56) 0.47
Incident JSN (from grade 0 to grade ≥ 1) 99 1.39 (0.50-3.88) 0.53
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 2) 86 1.36 (0.63-2.91) 0.44
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 1) 160 1.51 (0.82-2.79) 0.19
Progressive OST (increasing ≥ 1 grade from baseline OST ≥ 1) 76 0.55 (0.24-1.26) 0.16
Progressive JSN (increasing ≥ 1 grade from baseline JSN ≥ 1) 84 1.40 (0.64-3.03) 0.40
*Adjusted for age, race, gender, and body mass index.
6.1±1.3 years. There were no signiﬁcant interactions by race or
gender. The hazard ratios (Table) show no signiﬁcant relationships
between higher serum TGF-β1 and incident rOA, OST, or JSN
at the knee before or after adjustment. The odds of progressive
rOA by either K-L deﬁnition were 40- 50% higher in association
with higher serum TGF-β1 levels, but this association was not
statistically signiﬁcant. There was an apparent reduction in OST
progression with higher lnTGF-β1, also not statistically signiﬁcant.
Conclusions: Serum TGF-β1 levels do not predict development
of incident rOA, OST, or JSN in this longitudinal, population-based
study including AA and Caucasian men and women. The ﬁnding of
increased rOA K-L progression with higher serum TGF-β1 levels
did not reach statistical signiﬁcance, even in this largest study to
date of this biomarker, making it unlikely that serum TGF-β1 will
be a robust, stand-alone biomarker for future studies.
Reference
[1] Nelson AE. Osteoarthritis Cartilage in press 2009; doi:10.1016/
j.joca.2008.11.010.
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Purpose: Type II collagen is the major collagen of the articular
cartilage and it is gradually degraded during the pathogenesis of
osteoarthritis (OA). Measurement of collagen type II degradation
fragments may be associated with the progression of Osteoarthritis
(OA). It is appreciated that aggrecan degradation is a combina-
tion of MMP and aggrecanase activity, resulting in a distinct and
protease speciﬁc temporal release pattern, with aggrecanase ac-
tivity at early time-points and MMP activity at later time-points.
The release of collagen type II is less understood with respect
to the temporal release pattern, and the different proteolytic pro-
teases associated with that. We therefore identiﬁed three novel
MMP-mediated collagen type II degradation fragments of collagen
type II, and developed assays for that. We compared the release
pattern to that of CTX-II.
Methods: Human type II collagen (puriﬁed) and human articu-
lar cartilage was digested with a mix of MMPs. The digested
was analyzed on LC-MS/MS and peptide fragments were identi-
ﬁed/mapped by Mascot database search. Three neoepitopic se-
quences were chosen, synthesized and used as immunogen.
Fusions were made from the spleen of good-titer mice. After
cloning and screening, the best clones were chosen and the
monoclonal antibodies were puriﬁed and entered assay devel-
opment. All assays were designed as follows: 1) biotin-peptid
on streptavidin plates, 2) samples or standard, 3) Primary anti-
body, and 4) secondary HRP-antibody. Bovine explants cultures
treated with proinﬂammatory cytokines were used for testing the
biomarkers for native reactivity. Experiment including different pro-
teases inhibitors were conducted to validated the origin of the new
biomarkers. Established markers were measured in paralled for
comparison. Furthermore; the antibodies were tested for localiza-
tion by immunohistochemistry.
Results: Three assays were developed; CIIM538, CIIM1027 and
CIIM1053. All three assays were optimized in respect to incubation
buffer, time and temperature, as well as antibody concentrations.
Following technical speciﬁcation were established (on average):
Range - 1-500 ng/ml, lower detection limit 0.2 ng/ml, dilution recov-
ery 95-120%, intra- and inter-assay CVs < 6% and 11%, respec-
tively. Measuring time-dependent release of the new biomarkers
showed that the new type II collagen assays could proﬁle the
degradation of cartilage as a function of time. The releases of
CIIM538 and CIIM1027 are signiﬁcantly increased when treated
with O+T for 13-15 days. These results show similar pattern to the
release observed when we measure MMP-generated aggrecan
fragments (342-G2). The third MMP-derived marker, CIIM1053,
seems to displace the release to later time points, which resem-
bles the release pattern of CTX-II. Furthermore the signal was
inhibited when MMP inhibitor, but not other protease inhibitors,
was added to the cultures.
Conclusions: We have developed three new biomarkers of type II
collagen, speciﬁc for MMP neoepitopic sites in the helical region.
These three assays display different release patterns; suggesting
the use of these in proﬁling different stages or processes of carti-
lage degradation. The combination of several markers is needed
for the understanding biological processes in preclinical settings,
and these assay aid the understanding to distinct and relevant dis-
ease related processes. In a near future, we will introduce clinical
sample to these assays in hope of developing important clinical
tools.
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Purpose: Quantitative determination of cartilage degradation is
important information for the assessment of patients with joint dis-
eases, however, until now in vitro diagnostic products have failed
to provide the necessary sensitivity and speciﬁcity. We therefore
wanted to investigate the clinical utility of a series of new sandwich
immunoassays quantitating different pools of aggrecan fragments
carrying neo-epitopes generated by the proteolytic cleavage of
aggrecanase and matrix metalloproteinases (MMPs).
